Innovative Medicine

Innovative Medicine

March 20, 2019

Johnson & Johnson Joins Forces with Monash University-led Partnership to Advance Novel Technology Aimed at Saving Lives of Women in Child Birth

Innovative Medicine

March 18, 2019

XARELTO® (rivaroxaban) Significantly Reduced the Risk of Overall Strokes and the Most Severe Strokes and Was Associated with Fewer Stroke-Related Deaths in the Real World Versus Warfarin in Patients with Nonvalvular Atrial Fibrillation

Innovative Medicine

March 15, 2019

Interim Analysis Showed Treatment with OPSUMIT® (macitentan) Associated with Significant Improvement in Right Ventricular (RV) Function and Pulmonary Vascular Resistance (PVR) in Patients with Pulmonary Arterial Hypertension (PAH)

Innovative Medicine

March 12, 2019

Janssen Submits Application to U.S. FDA Seeking Approval of DARZALEX® (daratumumab) Combination Therapy for Patients with Newly Diagnosed Multiple Myeloma Who Are Transplant Ineligible

Innovative Medicine

March 11, 2019

XARELTO® (rivaroxaban) Significantly Reduced Ischemic Stroke in Patients with Nonvalvular Atrial Fibrillation in Large, Real-World Meta-Analysis of Non-Vitamin K Antagonist Oral Anticoagulants (NOACs)

Innovative Medicine

March 11, 2019

New Phase 3 Stelara® (Ustekinumab) Data Show Positive Results as Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

Innovative Medicine

March 5, 2019

Janssen Announces U.S. FDA Approval of SPRAVATOTM (esketamine) CIII Nasal Spray for Adults with Treatment-Resistant Depression (TRD) Who Have Cycled Through Multiple Treatments Without Relief

Innovative Medicine

February 27, 2019

Janssen Announces U.S. FDA Approval of Novel TREMFYA® (guselkumab) One-Press Patient-controlled Injector for Adults with Moderate-to-Severe Plaque Psoriasis

Corporate

February 15, 2019

Johnson & Johnson Innovation Names Winners of Inaugural Champions of Science – Africa Storytelling Challenge